



BRAZILIAN JOURNAL OF MICROBIOLOGY

<http://www.bjmicrobiol.com.br/>



Letter to the Editor

Is a dose of 17D vaccine in the current context of Yellow Fever enough?



Dear Editor,

The availability of the effective 17D vaccine as well as an eradication program of *Aedes aegypti* dramatically decreased the urban Yellow Fever (YF) incidence in Americas.^{1,2} However, in the last decades, the YF transmission was reported outside endemic area (Amazon region), with extension of viral circulation toward to densely populated and highly *Aedes*-infested regions and low vaccination coverage.^{3–5}

Since 1990s, Yellow Fever virus (YFV) have been extending its traditional endemic area toward to Southern and South-eastern regions in Brazil.⁴ From July 2017, to epidemiological week 2, 2018, 470 YF cases were suspected in Brazil, 35 confirmed, and 20 deaths, with 411 epizootic confirmed.⁶

Besides, the susceptibility and competence of *Ae. aegypti* and *Aedes albopictus* to YFV transmission had been demonstrated and they can become active vectors in YF reemergence⁷ in YFV-free regions. The vector may be found in more than 130 countries with around 4 billion people at risk of introduction and spread of infection,⁸ highlighting the concern for the future about the YFV outbreaks. Considering this epidemiological scenario, the area to vaccine coverage has been expanding, following the current recommendation of World Health Organization (WHO), which a single dose of 17D vaccine confers life-long protection against YF.⁹

This decision is polemic for a series of reasons. Firstly, vaccine failures have already been demonstrated.^{3,10} Neutralizing antibodies levels may decrease significantly in adults and children eight and four years after primary vaccination, respectively,^{11,12} and the immunogenicity in children is lower. Besides, following 17D vaccination, the T cell response is invoked, contributing to protection against wild-type YFV¹³ and increasing the immune response. Studies have been also showing that even lower doses than standard may produce neutralizing antibodies levels.^{14,15} This strategy was already used in early epidemic in the Democratic Republic of Congo, as an option to stretch vaccine supplies,¹⁶ which 98% (95% CI, 96–99) of seroconversion. All these factors may suggest a benefit of a booster in endemic or epidemic circumstances. However, it is important to consider that the method to

measure antibody levels had low stringency (PRNT 50 rather than PRNT 80), which may result in detection of unspecific antibody. Besides, there is not correlation between protection and antibody titers.

In light of this information, the recommendation of a single dose of 17D vaccine might be not reasonable. We are suggesting the immediate vaccination to more than 90% of population (with fractional or full doses, respecting the contraindication), followed by vaccination campaign with full dose in the near future, and new studies about a single dose of 17D vaccine and response to fractional doses in different population and epidemiological context. Until then, due to vaccine failures already described, we believe at least two doses are recommended while as long as sufficient vaccines are available.

REFERENCES

1. Vasconcelos PF. Single shot of 17D vaccine may not confer life-long protection against yellow fever. *Mem Inst Oswaldo Cruz*. 2018;113(2):135–137.
2. Staples JE, Monath TP. Yellow fever: 100 years of discovery. *JAMA*. 2008;300(8):960–962.
3. Monath TP, Vasconcelos PF. Yellow fever. *J Clin Virol*. 2015;64:160–173.
4. Romano AP, Costa ZG, Ramos DG, et al. Yellow Fever outbreaks in unvaccinated populations, Brazil, 2008–2009. *PLoS Negl Trop Dis*. 2014;8(3):e2740.
5. Carvalho RG, Lourenço-de-Oliveira R, Braga IA. Updating the geographical distribution and frequency of *Aedes albopictus* in Brazil with remarks regarding its range in the Americas. *Mem Inst Oswaldo Cruz*. 2014;109(6):787–796.
6. Brazil. Monitoramento do Período Sazonal da Febre Amarela, Brasil – 2017/2018. Informe n. 9. Brasília: Ministério da Saúde; 2018:11.
7. Couto-Lima D, Madec Y, Bersot MI, et al. Potential risk of re-emergence of urban transmission of Yellow Fever virus in Brazil facilitated by competent *Aedes* populations. *Sci Rep*. 2017;7(1):4848.
8. Vasconcelos PF, Monath TP. Yellow fever remains a potential threat to public health. *Vector Borne Zoonotic Dis*. 2016;16(8):566–567.

9. Who. Vaccines and vaccination against yellow fever: WHO Position Paper, June 2013 – recommendations. *Vaccine*. 2015;33(1):76–77.
10. Belmusto-Worn VE, Sanchez JL, McCarthy K, et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arlvax and YF-VAX) in healthy infants and children in Peru. *Am J Trop Med Hyg*. 2005;72(2):189–197.
11. Campi-Azevedo AC, Costa-Pereira C, Antonelli LR, et al. Booster dose after 10 years is recommended following 17DD-YF primary vaccination. *Hum Vaccin Immunother*. 2016;12(2):491–502.
12. Cgfsyf. Duration of post-vaccination immunity against yellow fever in adults. *Vaccine*. 2014;32(39):4977–4984.
13. Hepburn MJ, Kortepeter MG, Pittman PR, et al. Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine. *Vaccine*. 2006;24(15):2843–2849.
14. Monath T, Gershman M, Staphles E, Barret A. Yellow fever vaccine. In: Plotkin S, Orenstein W, Offit P, eds. *Vaccines*. 6th ed. Saunders Elsevier; 2012:870–896.
15. Roukens AH, Vossen AC, Bredenbeek PJ, van Dissel JT, Visser LG. Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. *PLoS ONE*. 2008;3(4):e1993.
16. Ahuka-Mundeki S, Casey RM, Harris JB, et al. Immunogenicity of fractional-dose vaccine during a yellow fever outbreak – preliminary report. *N Engl J Med*. 2018.

Cassia Fernanda Estofolete, Mauricio Lacerda Nogueira*
 Fundação Faculdade Regional de Medicina de São José do Rio Preto (FUNFARME), Faculdade de Medicina de São José do Rio Preto (FAMERP), Hospital de Base de São José do Rio Preto, Laboratório de Pesquisas em Virologia, São José do Rio Preto, SP, Brazil

* Corresponding author at: Faculdade de Medicina de São José do Rio Preto (FAMERP), Avenida Brigadeiro Faria Lima, 5416, Vila São Pedro, São José do Rio Preto CEP: 15090-000, SP, Brazil.

Editor: Marina Baquerizo

E-mail: mnogueira@famerp.br (M.L. Nogueira).
 1517-8382/

© 2018 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<https://doi.org/10.1016/j.bjm.2018.02.003>

Available online 13 March 2018